Morgan Stanley
LIXTW

Morgan Stanley’s Lixte Biotechnology Warrants LIXTW Stock Holding History

Morgan Stanley’s Portfolio LIXTW Stock Details LIXTW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-21,053
Closed -$17K – 7774
2021
Q1 		$17K Buy
+21,053
New +$20.1K ﹤0.01% 6779

Other funds holding LIXTW

SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
WAM
Warberg Asset Management Winnetka, Illinois $600M AUM 23.37% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Morgan Stanley's LIXTW Position: Q2 2021 in Review

Morgan Stanley sold out of Lixte Biotechnology Warrants (LIXTW) in Q2 2021, closing a stake of 21,053 shares — an estimated $17K sold.

Morgan Stanley first reported a position in LIXTW in Q1 2021 and held it in 1 quarter. The position peaked at $17K in Q1 2021. 3 funds tracked by Wall St. Rank hold LIXTW as of Q2 2021.

  • Morgan Stanley reported no remaining Lixte Biotechnology Warrants position as of Q2 2021 after selling out during the quarter.
  • Morgan Stanley sold 21,053 Lixte Biotechnology Warrants shares in Q2 2021, an estimated $17K.
  • Morgan Stanley first reported a position in Lixte Biotechnology Warrants in Q1 2021 and held it in 1 quarter.
  • Morgan Stanley's Lixte Biotechnology Warrants position peaked at $17K in Q1 2021.
  • 3 funds tracked by Wall St. Rank held Lixte Biotechnology Warrants as of Q2 2021.

Based on Morgan Stanley's 13F filing for Q2 2021, filed 16 Aug 2021.